Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005260 · ClinicalTrials.gov registry record · Phase 4
Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 88
- Enrollment target
NCT05005260: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT05005260 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05005260, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study aims to assess analgesia efficacy between liposomal bupivacaine single injection interscalene blockade vs. continuous interscalene nerve block for patients undergoing primary total shoulder arthroplasty.
Interventions
- DRUG Bupivacaine HCl
- DRUG Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2023-03-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005260
The ClinicalTrials.gov registry entry for NCT05005260 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine HCl is the first listed.
NCT05005260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05005260 about?
NCT05005260 is a clinical study titled "Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty". This study aims to assess analgesia efficacy between liposomal bupivacaine single injection interscalene blockade vs. continuous interscalene nerve block for patients undergoing primary total shoulder arthroplasty.
What is the current status of trial NCT05005260?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 88 participants. The study started on 2021-10-14. Estimated completion is 2023-03-18.
What interventions are being tested in trial NCT05005260?
The interventions under investigation include: Bupivacaine HCl (DRUG), Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj (DRUG).
Who is sponsoring clinical trial NCT05005260?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.